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Both paclitaxel and S-1 are effective against gastric cancer, but the optimal regimen for combined chemotherapy with these drugs
remains unclear. This phase I/II study was designed to determine the maximum tolerated dose (MTD), recommended dose (RD),
dose-limiting toxicity (DLT), and objective response rate of paclitaxel in combination with S-1. S-1 was administered orally at a fixed
dose of 80mgm
 2day
 1 from days 1 to 14 of a 28-day cycle. Paclitaxel was given intravenously on days 1, 8, and 15, starting with a
dose of 40mgm
 2day
 1. The dose was increased in a stepwise manner to 70mgm
 2. Treatment was repeated every 4 weeks
unless disease progression was confirmed. In the phase I portion, 17 patients were enrolled. The MTD of paclitaxel was estimated to
be 70mgm
 2 because 40% of the patients given this dose level (two of five) had DLT. The RD was determined to be 60mgm
 2.I n
the phase II portion, 24 patients, including five with assessable disease who received the RD in the phase I portion, were evaluated.
The median number of treatment courses was six (range: 1–17). The incidence of the worst-grade toxicity in patients given the RD
was 28 and 8%, respectively. All toxic effects were manageable. The response rate was 54.1%, and the median survival time was 15.5
months. Our phase I/II trial showed that S-1 combined with paclitaxel is effective and well tolerated in patients with advanced gastric
cancer.
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Patients with unresectable and recurrent gastric cancer have
extremely poor outcomes, with 5-year survival rates of less than
5% (Parker et al, 1997). Various chemotherapy regimens have been
developed, but median survival in patients with unresectable or
recurrent gastric cancer (or both) who receive chemotherapy
remains less than 9–12 months (Wils et al, 1991; Kim et al, 1993;
Koizumi et al, 2003; Ohtsu et al, 2003; Ajani et al, 2006b).
Randomised phase III studies of combination chemotherapy for
unresectable advanced gastric cancer reported median survival
times (MSTs) of 5–9.6 months and overall response rates of
9–46% (Webb et al, 1997; Vanhoefer et al, 2000; Ross et al, 2002;
Ohtsu et al, 2003). Combination chemotherapy thus appears to
contribute only marginally to survival. New agents and combina-
tion chemotherapy regimens are needed to achieve greater survival
benefits in far-advanced gastric cancer.
S-1, a fourth-generation oral fluoropyrimidine, is an oral
formulation combining tegafur, 5-chloro-2,4-dihydroxypyridine,
and potassium oxonate at a molar ratio of 1:0.4:1 (Takechi et al,
1997). S-1 is acknowledged to be a useful anticancer drug in Japan.
Phase I and early phase II studies of S-1 as a single agent proposed
80mgm
 2day
 1 given orally for 28 consecutive days, followed by
a 2-week rest period, as the tentative recommended dosage
(Horikoshi et al, 1996; Sugimachi et al, 1999). A number of studies
have reported that S-1 monotherapy is effective against gastric
cancer, with response rates ranging from 26 to 53% (Horikoshi
et al, 1996; Sakata et al, 1998; Koizumi et al, 2000; Chollet et al,
2003). The toxicity profile of S-1 in European studies apparently
differs from that in Japanese studies, with more diarrhoea and
hand-foot syndrome and less myelotoxicity (Chollet et al, 2003). In
one early phase II clinical trial of S-1, the response rate was 53.6%
(15 out of 28), and the median survival period was 298 days in
Japanese patients with advanced gastric cancer (Horikoshi et al,
1996). Two late phase II studies of S-1 in advanced gastric cancer,
which used similar treatment regimens, demonstrated high
response rates of 49 and 44%, respectively (Sakata et al, 1998;
Koizumi et al, 2000). These results suggested that S-1 is likely to
become a key drug for the management of advanced gastric cancer.
Paclitaxel is a taxane derivative that was originally isolated from
Taxus brevifolia, a type of Western yew (Wani et al, 1971).
Paclitaxel, a newer taxane, has been shown to be effective against a
variety of cancers, including breast cancer (Holmes et al, 1991),
ovarian cancer (Einzig et al, 1992), and lung cancer (Chang et al,
1993). Paclitaxel is also an effective drug for gastric cancer, with
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sresponse rates ranging from 20 to 28% in single-agent phase II
studies (Ajani et al, 1998; Ohtsu et al, 1998; Yamada et al, 2001;
Yamaguchi et al, 2002). Ajani et al (1998) reported that a 24-h
infusion of paclitaxel is associated with a higher response rate and
milder haematological toxicity than a 3-h infusion of an equivalent
dose in patients with gastric cancer . The recommended optimal
dose of paclitaxel in Japan was determined to be 210mgm
 2 once
every 3 weeks (Yamaguchi et al, 2002). Recently, good results have
been obtained with a weekly regimen of paclitaxel in patients with
ovarian cancer and gastric cancer (Fennelly et al, 1997; Arai et al,
2003; Hironaka et al, 2006). The use of weekly regimens of
paclitaxel, used mainly as second-line chemotherapy, has in-
creased in Japan because of milder haematological toxicity as
compared with regimens administering paclitaxel once every 3
weeks.
This multi-institution phase I/II study was designed to evaluate
the efficacy and toxicity of combination therapy with paclitaxel,
given in increasing doses, plus a fixed dose of S-1 (80mgm
 2)i n
patients with untreated, advanced gastric cancer. All participating
centres belonged to the North Kanto Gastric Cancer Study Group.
PATIENTS AND METHODS
Patient eligibility
Eligible patients had histologically proved unresectable or
recurrent gastric cancer. Up to one regimen of prior chemotherapy
was allowed (adjuvant chemotherapy was allowed provided that at
least 28 days had elapsed since the last treatment), except for prior
treatment with taxanes (paclitaxel or docetaxel).
Other inclusion criteria were as follows: an age of 20–75 years; a
performance status of 0–1 (Eastern Clinical Oncology Group); an
estimated life expectancy of more than 3 months; a white blood cell
count between 4000 and 12000mm
 3; an absolute neutrophil
count of over 2000mm
 3, a platelet count of over 100000mm
 3,a
haemoglobin level of over 8.0gdl
 1; aspartate aminotransferase
and alanine aminotransferase levels within two times the upper
limit of normal for the institution; a serum bilirubin level of less
than 1.5mgdl
 1; a serum creatinine level within the upper limit of
the normal value for the institution; a 24-h creatinine clearance of
more than 50mlmin
 1; and a normal electrocardiogram. Only
patients who could swallow tablets were eligible. Patients were
excluded if they had brain metastases, severe comorbid conditions,
active double cancers, a past history of drug allergy, or were unable
to comply with the protocol requirements. Pregnant women were
also excluded. Written informed consent was obtained from all
patients before study entry. This study was approved by the Ethics
Committees at the participating sites.
Treatment regimen and dose-escalation schedule
S-1 (Taiho Pharmaceutical Co., Ltd., Tokyo, Japan) was given
orally twice daily after meals at a fixed dose of 80mgm
 2day
 1 for
14 consecutive days, followed by a 14-day rest period; this cycle
was repeated every 4 weeks. The dose of S-1, decided on the basis
of the patients’ body surface area (BSA), was 40mg (BSA
o1.25m
2), 50mg (BSA 1.25–1.5m
2), or 60mg (BSA X1.5m
2).
Paclitaxel (Taxol; Bristol-Myers Squibb, Tokyo, Japan) was
administered intravenously over the course of 60min on days 1,
8, and 15. To prevent hypersensitivity reactions, all patients
received 20mg of dexamethasone intravenously, 50mg of diphen-
hydramine orally, and 50mg of ranitidine intravenously 1h before
paclitaxel infusion. The initially administered dose of paclitaxel
was 40mgm
 2 (dose level 1). The dose was scheduled to be
increased in 10mgm
 2 increments to 70mgm
 2 (dose level 4),
unless the maximum tolerated dose (MTD) was reached. At least
three patients received each dose level. If one of the three patients
at a given dose had any dose-limiting toxicity (DLT), three other
patients were assigned to receive the same dose. If one of the
resulting six patients had DLT, the dose could be increased to the
next level; if two or more patients had DLT, that level was deemed
the MTD. If DLT occurred in two or all three of the patients
initially assigned to a given dose level, that level was also
considered the MTD. The MTD was thus defined as the dose at
which 433% of the patients had DLTs during the first course of
treatment. The recommended dose (RD) for phase II studies was
defined as one level below the MTD. Toxicity was graded according
to the National Cancer Institute common toxicity criteria, version
2.0. Dose-limiting toxicity was defined as follows: grade 4
leucopenia/neutropenia, febrile grade 3 neutropenia lasting for
more than 4 days, grade 3 thrombocytopenia, and any grade 3 or
above non-haematological toxicity (excluding anorexia, nausea,
vomiting, alopecia, and general fatigue).
Response evaluation and toxicity
Tumour response was evaluated by computed tomographic (CT)
scans for each course of treatment. Imaging studies were repeated
to confirm response at least 4 weeks (for complete or partial
responses) after first documenting a given response. Thereafter,
tumour response was evaluated by CT scanning every two cycles.
Radiographs of all assessable patients were also reviewed
externally to confirm investigator-designated responses. Tumour
response was objectively evaluated according to guidelines for the
evaluation of the response of solid tumours to treatment (Therasse
et al, 2000).
End points and statistical analysis
The primary study end point was the definition of the MTD and
DLT of the described regimen of TS-1 plus paclitaxel. The MTD
and recommended dose were further examined in additional
patients to confirm their toxicity/safety profile and to ensure their
suitability for future phase II trials. Additional study end points
were to determine (i) the objective response rate according to the
RECIST criteria; (ii) progression-free survival (calculated from the
date of starting treatment to the date of progression or relapse);
and (iii) overall survival. Survival from the date of study entry was
estimated using the Kaplan–Meier product-limit method.
The calculation of sample size for the phase II portion of the
study was based on a target activity level of 60% and a minimum
activity level of 30%, at a significance level of 0.05 and b
error¼0.1. The required number of patients was estimated to
be 21.
RESULTS
Patients’ characteristics
Between August 2002 and April 2005, a total of 36 patients were
enrolled. In the phase I part, 17 patients were studied between
August 2002 and January 2004. The patients’ characteristics are
summarised in Table 1. Their median age was 62 years (range:
44–71 years). One patient had undergone a prior gastrectomy, and
another patient had received adjuvant chemotherapy with S-1
alone before study entry. Histologically, 12 patients had intestinal-
type adenocarcinoma, and five patients had diffuse-type adeno-
carcinoma. The sites of metastasis were the liver in two patients,
the lymph nodes in 15, and the peritoneum in five. One
patient (level 3) had a non-measurable metastatic lesion in the
peritoneum.
In the phase II part of the study, 19 patients were enrolled
between August 2004 and April 2005 (Table 1). Their median age
was 63 years (range: 48–75 years). Four patients had undergone a
prior gastrectomy and received adjuvant chemotherapy with S-1
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salone before study entry. Histologically, 13 patients had intestinal-
type adenocarcinoma, and six patients had diffuse-type adeno-
carcinoma. All 19 patients had measurable metastatic lesions,
involving the lymph nodes in 14 patients and the liver in six. Nine
patients (47%) had non-measurable metastatic lesions in the
peritoneum.
A total of 201 courses of treatment were given. The median
number of treatment courses was four (range: 1–13) and six
(range: 1–17) in the phase I and II portions, respectively. The
median duration of therapy per patient was 251 days (range: 28–
523) in the phase II portion.
Determination of MTD
Toxic effects are summarised in Table 2. In the phase I part of the
study, all patients were evaluated for adverse reactions, and 16
completed one or more cycles of treatment. None of the six
patients given dose level 1 or 2 had DLT. At level 3, one patient had
grade 3 leucopenia during the first cycle, and another had grade 3
anaemia during the second. Three other patients were then
assigned to receive dose level 3 to reconfirm safety; none had DLT.
At level 4, one patient had grade 3 anorexia (20%) with grade 3
diarrhoea (20%) and vertigo (20%) during the first cycle, whereas
another had grade 3 hyperkalemia (20%). The plasma potassium
concentration increased after treatment with paclitaxel and then
gradually fell to the normal range. Vertigo occurred 30–40min
after the administration of paclitaxel. These toxic effects repeatedly
occurred after treatment with paclitaxel and resolved completely
without any medication. They were therefore considered treat-
ment-related. Dose-limiting toxicity occurred in two of the five
patients given dose level 4. On the basis of these results, dose level
4 was considered the MTD, and dose level 3 was determined to be
the RD.
Efficacy
In the phase I portion, one of the 17 patients had no measurable
lesions. Efficacy was evaluated in the other 16 patients. Seven
Table 1 Patients’ characteristics
Phase I (n¼17) Phase II (n¼19)
Median age, years (range) 64 (44–71) 63 (48–75)
Male/female 12/5 15/4
Performance status
01 4 1 5
13 4
Histological type
Intestinal 12 13
Diffuse 5 6
Prior therapy
None 15 15
Gastrectomy 1 0
Gastrectomy+chemotherapy 1 4
Site of metastasis
Liver 2 6
Lymph nodes 15 14
Peritoneum 5 0
Table 2 Toxic effects and number of patients with toxicity according to the dose level of paclitaxel
Paclitaxel
Level 1 (n¼3) Level 2 (n¼3) Level 3 (n¼6) Level 4 (n¼5)
Grade 1–2 3–4 1–2 3–4 1–2 3–4 1–2 3–4
Haematological
Leucopenia 2 0 1 03100
Neutropenia 2 0 0 02010
Anaemia 1 0 2 02110
Thrombocytopenia 0 0 0 00000
Non-haematological
Anorexia 0 0 1 02001
Nausea 1 0 0 01010
Diarrhoea 0 0 0 01001
Fatigue 0 0 0 02010
Stomatitis 1 0 0 00000
Rash 0 0 0 00010
Vertigo 0 0 0 00001
Bilirubin 0 0 0 00010
AST/ALT 0 0 0 00020
Hyperkalemia 0 0 0 00001
AST¼aspartate aminotransferase; ALT¼alanine aminotransferase; n¼number of patients. National Cancer Institute common toxicity criteria (version 2).
Table 3 Overall response to treatment
n CR PR SD PD NE RR (%)
Phase I
Overall 17 0 7 2 7 1 43.7
Level
1 3 0 1 0 2 0 33.3
2 3 0 2 1 0 0 66.6
3 6 0 2 1 2 1 50.0
4 5 0 2 0 3 0 40.0
Histological type
Intestinal 12 0 4 2 5 1 36.3
Diffuse 5 0 3 0 2 0 60.0
Phase II
a
Overall 24 1 12 6 5 0 54.1
Histological type
Intestinal 17 1 9 3 4 0 58.8
Diffuse 7 0 3 3 1 0 42.8
CR¼complete response; PR¼partial response; SD¼stable disease; PD¼progres-
sive disease; NE¼not evaluated; RR¼response rate.
aIncluding five patients assigned
to level 3 in the phase I portion.
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spatients had a partial response (PR), two had stable disease (SD),
and seven had progressive disease (PD), yielding a response rate of
43.7% in patients with assessable lesions (Table 3). The response
rate was 36.3% (four out of 11) in the patients with intestinal-type
adenocarcinoma and 60% (three out of five) in those with diffuse-
type adenocarcinoma (Table 3).
Twenty-four patients, including five enrolled in the phase I
portion of the study, were evaluated to determine the response rate
at the RD in the phase II portion. The overall response rate was
54.1% (95% confidence interval (CI): 34.2–74.1%); one patient had
a complete response (CR), 12 had PR, six had SD, and five had PD
(Table 3). The response rate according to pathological type was
58.8% (10 out of 17) for intestinal-type adenocarcinoma and 42.8%
(three out of seven) for diffuse type. The median overall duration
of response in the 13 responders in the phase II portion was 7.8
months (95% CI, 4.2–10.1 months). The median time to
progression (TTP) was 9.5 months (95% CI, 5–11.6 months) in
the phase II portion (Figure 1). Median survival time in the phase
II portion was 15.5 months (95% CI, 11.6–19.4 months), and the
1- and 2-year survival rates were 71.7 and 49.3%, respectively
(Figure 2).
Toxicity
In the phase II portion, the median number of courses
administered was six (range: 1–17). In the 25 patients who
received the RD, including the six patients assigned to level 3 in the
phase I portion, the most frequent types of severe (grades 3 and 4)
haematological toxicity were leucopenia (five cases, 20%),
neutropenia (five cases, 20%), and thrombocytopenia (four cases,
16%), as shown in Table 4. The most common types of non-
haematological toxicity were stomatitis (seven cases, 28%), nausea
(five cases, 20%), and rash (five cases, 20%). Among the 25
patients in the phase II portion, the dose of paclitaxel was reduced
in three patients within one cycle because of neutropenia and
thrombocytopenia. The incidence of the worst-grade toxicity in
patients given the RD was none in seven patients (28%), grade 1 in
four (16%), grade 2 in five (20%), grade 3 in seven (28%), and
grade 4 in two (8%). There was no treatment-related death or
delayed severe toxicity.
DISCUSSION
This study was undertaken to determine the RD for phase II
studies of paclitaxel combined with S-1 for advanced metastatic
gastric cancer and to investigate the antitumour effect and
feasibility of this combination. The RD was determined to be
60mgm
 2 of paclitaxel on days 1, 8, and 15 plus 80mgm
 2day
 1
of S-1 on days 1–14 of a 28-day cycle. The response rate at the RD
was 54.1%, with an MST of 15.5 months, and a TTP of 9.5 months.
These are promising results in patients with advanced metastatic
gastric cancer. Moreover, toxicity was not severe, and therapy
could be administered on an outpatient basis.
Two late phase II trials of S-1 therapy in Japanese patients with
advanced gastric cancer have reported a high overall response rate
of 44–49% and an MST of 7–8 months (Sakata et al, 1998;
Koizumi et al, 2000). These findings suggest that S-1 is one of the
most effective currently available antitumour agents for gastric
cancer. To further enhance efficacy and improve survival, several
ongoing studies are assessing the response to S-1 combined with
other anticancer agents with different mechanisms of action.
Clinically, paclitaxel has been used in combination with 5-
fluorouracil (5-FU) and its derivatives for several reasons. First,
paclitaxel is considered an effective drug for gastric cancer, with
response rates ranging from 20 to 28% in single-agent phase II
studies (Ajani et al, 1998; Ohtsu et al, 1998; Yamada et al, 2001;
Yamaguchi et al, 2002). Furthermore, Ajani et al (2006a) reported
that sequential treatment with paclitaxel and bryostatin-1 is
effective, with a response rate of 29%. Paclitaxel is a good
candidate for combined treatment because of it lacks cross-
resistance to fluoropyrimidine derivatives. S-1 and paclitaxel have
different mechanisms of action, and the principal toxicities of
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Figure 1 Cumulative probability of progression-free survival as esti-
mated by the Kaplan–Meier method in 24 patients.
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Figure 2 Cumulative probability of overall survival as estimated by the
Kaplan–Meier method in 24 patients.
Table 4 Adverse events observed in 25 patients
Number of patients (%)
Adverse events Grade 3 Grade 4 Grade 3 or 4
Haematological
Leucopenia 5 0 5 (20)
Neutropenia 3 2 5 (20)
Anaemia 2 0 2 (8)
Thrombocytopenia 4 0 4 (16)
Non-haematological
Anorexia 2 0 2 (8)
Nausea 4 1 5 (20)
Diarrhoea 1 0 1 (4)
Fatigue 2 0 2 (8)
Stomatitis 6 1 7 (28)
Rash 5 0 5 (20)
National Cancer Institute common toxicity criteria (version 2).
S-1 combined with paclitaxel
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sthese drugs do not overlap (Fujitani et al, 2005). In recent years,
weekly regimens of paclitaxel, based on its mechanism of action,
have been widely studied. One study comparing a weekly infusion
of paclitaxel with an infusion once every 3 weeks documented
similar efficacy with decreased adverse reactions (in particular,
myelosuppression and peripheral neuropathy) with the weekly
regimen in women with ovarian cancer (Andersson et al, 2000). A
combination of paclitaxel and 5-FU has been demonstrated to have
additive cytotoxicity against tumour cell lines in vitro, especially
strong with sequential exposure (Kano et al, 1996). Moreover,
Kondo et al (2005) reported a MST of 335 days in a phase I study
of weekly paclitaxel plus 5-FU in patients with advanced gastric
cancer. The second reason for combining paclitaxel with 5-FU is
that their principal toxicities differ considerably. Neuropathy and
neutropenia are the principal toxicities of paclitaxel, whereas
stomatitis and diarrhoea are the predominant toxicities of
fluoropyrimidines in most commonly used regimens (Bokemeyer
et al, 1997; Cascinu et al, 1998). We therefore combined paclitaxel
with S-1.
As most toxic effects of S-1 occurred after 4 consecutive weeks
of treatment in phase II studies, S-1 was administered daily at a
fixed dose of 80mgm
 2 for 2 consecutive weeks in combination
with paclitaxel on days 1, 8, and 15 of a 28-day cycle. This duration
of treatment with S-1 was 2 weeks shorter than the time at which
toxicity such as leucopenia generally appears. We studied this
regimen in a phase I/II trial in patients with unresectable or
recurrent advanced gastric cancer.
The main objective of our phase I study was to evaluate the
safety and optimal dose of paclitaxel in combination with S-1. The
incidences of grades 3 and 4 toxic effects in our study are
consistent with those reported previously for the same S-1
combination regimen (Ajani et al, 2006b; Inokuchi et al, 2006).
When paclitaxel was administered every 3 weeks with or without
5-FU, non-haematological toxicity, apart from alopecia of grade 3
or higher, included neuropathy (0–29%), myalgia (0–27%), and
nausea/vomiting (0–7%) (Ohtsu et al, 1998; Yamada et al, 2001;
Arai et al, 2003; Hokita et al, 2005; Kondo et al, 2005; Inokuchi
et al, 2006). Although there are limitations in comparing the
results of different studies because of differences in factors such as
the dose and treatment schedule of paclitaxel therapy and the
extent of prior treatment, neuromuscular toxicity, the most
common adverse effect of paclitaxel, was very mild in our study.
The good tolerability of our regimen is reflected in the fact that
patients received a median of six treatment courses in the phase II
portion.
An MST of at least 12 months and a TTP of at least 8 months
would strongly suggest a significant advance in the treatment of
advanced gastric cancer (Ajani et al, 2006b). In our phase I/II
study, the response rate was 54.1% and the MST was 15.5 months.
The MST in our study was longer than that in previous phase II
studies of S-1 as a single agent (207–250 days) (Sakata et al, 1998;
Koizumi et al, 2000). Our response rate is equivalent to that
reported for TS-1/cisplatin therapy (Koizumi et al, 2003). More-
over, the MST in our study was longer than the 383 days obtained
in a previous study of S-1 combined with cisplatin (Koizumi et al,
2003). The incidences of grade 3 or 4 haematological and non-
haematological toxicity were similar to those with S-1 plus
cisplatin (Koizumi et al, 2003; Ajani et al, 2006b). The high
response rate and longer MST in our study may be related to the
better performance status of our patients as compared with that in
other studies. With cisplatin-based regimens, patients must receive
intravenous infusions to ensure adequate hydration and prevent
cisplatin-induced renal damage. S-1 combined with paclitaxel
might therefore be better suited for treatment on an outpatient
basis than cisplatin-based chemotherapy. A high response rate
coupled with a better quality of life is considered an advantage of
S-1 plus paclitaxel.
In 2005, Hokita et al (2005) reported the results of a phase I
study of S-1 combined with paclitaxel in patients with advanced
gastric cancer. The response rate was 53%, and the MST was 428
days. Furthermore, Fujitani et al (2005) reported a preliminary
response rate of 62.5% (five out of eight) in their phase I study of
S-1 plus weekly paclitaxel in patients with advanced gastric cancer.
These response rates and MST are comparable to those in our
study. A variety of taxane-based combination chemotherapy
regimens have been developed for advanced gastric cancer,
steadily improving response rates. Ajani et al (2005) reported that
a combination of docetaxel, cisplatin, and fluorouracil is highly
active against advanced untreated gastric or gastroesophageal
adenocarcinoma. Docetaxel has also been combined with TS-1, and
available evidence indicates that this combination is effective and
well tolerated in patients with advanced gastric cancer (Yamaguchi
et al, 2006).
In conclusion, our phase I/II trial suggests that S-1 combined
with paclitaxel is effective and well tolerated. Because this was a
small, uncontrolled study, phase III trials of S-1 plus paclitaxel are
needed to confirm benefits in terms of survival and quality of life
in patients with advanced gastric cancer, thereby establishing the
value of this new regimen. At present, a randomised study
comparing TS-1 plus paclitaxel with TS-1 plus cisplatin is being
carried out by the North Kanto Gastric Cancer Study Group.
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